Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|June 7, 2021
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective StudyNicolas Epaillard, Pauline Parent, Yohann Loriot, et al.
Cancer Medicine|September 5, 2024
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancerEduardo Terán, Rebeca Lozano, César A Rodríguez, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
European Urology Oncology|July 17, 2019
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer PatientsLucía Oliva, Rebeca Lozano, Casilda Llácer, et al.
Journal of Clinical Medicine|February 27, 2026
Effects of a 12-Week Supervised Exercise Program on Quality of Life, Functional Capacity, and Biological Parameters in Women with Breast Cancer: A Prospective Pilot ProgramGema Barrientos Vicho, Luis Posado-Dominguez, José David Urchaga, et al.
Cancers|June 18, 2020
Clinical Applications of Molecular Biomarkers in Prostate CancerFelipe Couñago, Fernando López-Campos, Ana Aurora Díaz-Gavela, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
British Journal of Cancer|August 23, 2018
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, et al.
Pageof 3